ArticleWorld journal of gastroenterology2025
Herbal medicine as a potential treatment for non-alcoholic fatty liver disease.
Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mapping the global research output of Traditional Chinese Medicine in the treatment of metabolic dysfunction-associated steatotic liver disease: a comprehensive bibliometric analysis based on multiple databases (2000-2025).Frontiers in medicine · 2026Pooled it
- Computational-experimental study reveals direct target and bioactives of Ajania fruticulosa against NAFLD via TLR2/NF-κB/PPAR-γ signaling.NPJ science of food · 2026Article
- Deciphering the hepatoprotective mechanism of Sarcopyramis nepalensis wall against non-alcoholic fatty liver disease by network pharmacology and experimental validation.Scientific reports · 2025Article
- Beyond biomarkers: An integrated traditional Chinese medicine-machine learning approach predicts hepatic steatosis in high metabolic risk populations.World journal of gastroenterology · 2025Article
- Identification of immune and major depressive disorder-related diagnostic markers for early nonalcoholic fatty liver disease by WGCNA and machine learning.Frontiers in bioinformatics · 2025Article
- Flavonoids as modulators of gut-liver axis: emerging therapeutic strategies for MAFLD.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) has emerged as a global public health concern, affecting over one-quarter of the global population. It is closely associated with the prevalence of obesity and metabolic syndrome. Current treatment options for NAFLD are limited and often have side effects. Traditional Chinese medicine (TCM) offers a promising alternative with its holistic approach and use of multi-component herbal formulations. A recent study explored the potential of the TCM formula, "Fanlian Huazhuo Formula (FLHZF)", to alleviate high-fat diet-induced NAFLD by regulating autophagy and lipid synthesis signaling pathways. TCM has shown advantages in the prevention and treatment of NAFLD due to its efficacy and minimal side effects. However, the complex multicomponent and multitarget characteristics of formulas such as FLHZF present challenges in research. Future studies should focus on utilizing modern techniques to deepen our understanding of the mechanisms of action and active ingredients of Chinese herbal medicines, thereby promoting their modernization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.